Gilead agrees to acquire Ouro Medicines

Gilead Sciences announced an agreement to acquire Ouro Medicines and its autoimmune-disease T-cell-engager program. The proposed Galapagos collaboration was a separate contemplated arrangement. Closing was later announced June 4, 2026.